Christopher Nixon Cox's most recent trade in Alto Neuroscience Inc. was a trade of 25,236 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 25,236 | 25,236 | - | - | Stock Option (right to buy) | |
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | 06 Feb 2024 | 1,250,000 | 0 | - | - | Series B Preferred Stock | ||
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | 06 Feb 2024 | 588,898 | 588,898 | - | - | Common Stock | ||
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | 06 Feb 2024 | 281,917 | 0 | - | - | Series C Preferred Stock | ||
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | 06 Feb 2024 | 126,755 | 715,653 | - | - | Common Stock | ||
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 30,574 | 30,574 | - | - | Stock Option (right to buy) | |
Alto Neuroscience Inc. | Christopher Nixon Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 4,623 | 4,623 | - | - | Stock Option (right to buy) |